<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341038</url>
  </required_header>
  <id_info>
    <org_study_id>TACRO-BELL-COVID</org_study_id>
    <secondary_id>2020-001445-39</secondary_id>
    <nct_id>NCT04341038</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury</brief_title>
  <acronym>TACROVID</acronym>
  <official_title>Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the days until reaching clinical stability
      after starting randomization in hospitalized patients with elevated inflammatory parameters
      and severe COVID-19 lung injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unfortunately, the treatment of COVID-19 disease is still based on life support therapies.
      Nowadays, there is no scientific evidence from clinical trials regarding the efficacy or
      safety of different drugs to treat COVID-19 patients, despite some of them evolving to fatal
      severe lung injury due to important inflammatory process secondary to pro-inflammatory
      cytokines. Interestingly, Tacrolimus has been shown to inhibit both pro-inflammatory
      cytokines and, also, human coronavirus SARS-Cov replication, but it has not specifically been
      tested in COVID-19 patients.

      Our working hypothesis is that severe SARS-CoV-2 (COVID-19) pneumonia is secondary to a
      deleterious inflammatory process; so, the use of Methylprednisolone pulses and Tacrolimus in
      hospitalized severe COVID-19 lung injury patients might have a positive clinical effect.

      Given the COVID-19 current health emergency, this study could provide useful evidence to
      treat some COVID-19 patients with Methylprednisolona and Tacrolimus, which might represent a
      new therapeutic option for them. Tacrolimus is a drug with more than 20 years of experience,
      and therefore, its side effects are well known and usually reversible. In addition, since
      tacrolimus is a low-cost and easy to produce at large-scale drug, it could be used to treat a
      large number of patients. The administration of this drugs could not only decrease mortality
      secondary to lung involvement by COVID-19, but also decrease the excessive burden of care
      that intensive care units are bearing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The statistician who will finally carry out the analyses will be blind to the treatment received by the patients</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to reach clinical stability</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the days until clinical stability is achieved after initiating randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury.
Clinical stability is defined if all the following criteria are met for 48 consecutive hours: Body temperature ≤ 37.0ºC; PaO2 / FiO2&gt; 400 and / or SatO2 / FiO2&gt; 300; Respiratory rate ≤ 24 rpm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach an afebrile state for 48 hours.</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach PaO2 / FiO2&gt; 400 and / or SatO2 / FiO2&gt; 300</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach FR ≤ 24 rpm for 48 hours</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of D-dimer (&lt;250 ug / L)</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until PCR normalization (&lt;5mg / L).</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until normalization of ferritin (&lt;400ug / L)</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of immunosuppressive treatment on viral load using quantitative PCR</measure>
    <time_frame>56 days</time_frame>
    <description>viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hospital discharge</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ventilatory support devices</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration that it is necessary to maintain ventilatory support.</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 mortality</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>56 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission</measure>
    <time_frame>56 days</time_frame>
    <description>cytokines quantification technique by Luminex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.</measure>
    <time_frame>56 days</time_frame>
    <description>IDIBELL Clinical Research and Clinical Trials Unit will oversee the monitoring and pharmacovigilance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>COVID-19</condition>
  <condition>Lung Injury</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.
In addition, these patients can receive all the treatments considered necessary for their clinical management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>the necessary dose to obtain blood levels of 8-10 ng / ml</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Advagraf®, Modigraf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>120mg of methylprednisolone daily for 3 consecutive days</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Urbason®, Solu-Moderín®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 infection confirmed by PCR

          -  New onset radiological infiltrates

          -  Respiratory failure (PaO2 / FiO2 &lt;300 or satO2 / FiO2 &lt;220)

          -  PCR&gt;100 mg/L and/or D-Dimer&gt;1000 µg/L and/or Ferritin&gt;1000 ug/L

          -  Informed consent.

        Exclusion Criteria:

          -  Life expectancy ≤ 24h

          -  Glomerular filtration ≤ 30 ml / min / 1.73 m2

          -  Leukopenia ≤ 4000 cells / µL

          -  Concomitant potentially serious infections.

          -  Contraindication for the use of tacrolimus according to the specifications of the
             product

          -  Known adverse reactions to treatment

          -  Have participated in a clinical trial in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Corbella, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitari de Bellvige</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Solanich, MD</last_name>
    <phone>0034 932607500</phone>
    <phone_ext>8946</phone_ext>
    <email>xsolanich@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Solanich, MD</last_name>
      <phone>0034 932607500</phone>
      <phone_ext>8946</phone_ext>
      <email>xsolanich@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Xavier Solanich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnau Antolí, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Xavier Solanich</investigator_full_name>
    <investigator_title>Xavier Solanich, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

